

CERTIFICATE OF ANALYSIS

Adamax - 10 mg


Modified Semax-type project reference - identity defined by qualified standard

Material	Adamax	Client	novumpeptides.com	Received	2026-08-31 at 2-8 C
Batch / lot	PEP-46-N7V	Label claim	10 mg	Analysed	2026-09-01 to 2026-09-02

TEST RESULTS

ATTRIBUTE	RESULT	SPECIFICATION	METHOD	VERDICT
Identity	Conforms	Matches reference	MA-MS-014 / LC-HRMS	Conforms
Purity (area %)	99.43%	$\geq 99.00\%$	MA-UHPLC-031 / UV 214	Pass
Largest single impurity	0.17%	$\leq 0.50\%$	MA-UHPLC-031 / UV 214	Pass
Total related substances	0.57%	$\leq 1.00\%$	MA-UHPLC-031 / UV 214	Pass
Adamax per vial	9.98 mg	9.00-11.00 mg	MA-ASSAY-011 / UHPLC-UV	Pass
Water content	4.21%	$\leq 8.00\%$	MA-KF-004 / Karl Fischer	Pass
Residual acetonitrile	184 ppm	≤ 410 ppm	MA-GC-006 / HS-GC-FID	Pass
Residual TFA	0.08%	$\leq 1.00\%$	MA-IC-003 / ion chromatography	Pass

RP-UHPLC processed trace, UV detection



Record S5KGN7V-PEP-01; duplicate independent preparations. System suitability met retention-time and resolution criteria; blank response was below threshold.

Related species > 0.05%

deletion sequence	0.17%
insertion sequence	0.13%
diastereomeric variant	0.09%
N-terminal variant	0.07%
C-terminal variant	0.05%
unresolved peaks	0.06%

Related species were assigned by orthogonal reference comparison and mass-spectrometric or chromatographic evidence. Mean area percentages; reporting threshold 0.05%.

Conclusion

Identity and quality attributes met the stated criteria. Mean Adamax content was 9.98 mg/vial and chromatographic purity was 99.43%.

Adamax nomenclature is not standardised; identity for this project is defined exclusively by the qualified project reference standard and its LC-HRMS fingerprint.

Analytical review

Ines Abadi

I. Abadi

Quality review

Marcus Oyelaran

Approval date: 2026-09-03

M. Oyelaran

Decision rule: guarded acceptance; reported outcomes account for method uncertainty and remain within the stated project specifications.